🔗 Share this article

Given that the United States continues making unprecedented adjustments to its vaccine recommendations, one figure has surfaced in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by casting doubt on COVID-19 shots throughout the pandemic and has focused upon possible deaths following Covid vaccination in her brief time at the Food and Drug Administration.

Proposed Changes to Childhood Vaccine Program

Health officials had intended to announce major changes to the childhood immunization program in December, bringing the US with the Danish immunization schedule, according to reports – a major change that would put the US at odds with a large portion of the international standard with insufficient data for benefit. This reveal has been delayed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to present at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending some pediatric immunization guidelines in the US so as to align more like the Danish model, a country with universal health coverage and a population approximately the population of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccines – usually the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Qualifications

Høeg has no obvious track record in pharmaceutical research, regulation or management, which has been typical for former leaders of the biologics center. She has served at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former directors of the center would “understand laws and regulations and the science of drug development”, noted a former acting FDA commissioner. “Frankly, she lacks the kind of background that prior appointees who headed the center have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner stated.

“Everybody just focuses on the new drug program, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and each of these must be managed,” she said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant leadership component to the position, which oversees in excess of 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” the former official said.

Official Statement and Contentious Initiatives

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment indicates increased cooperation among regulatory chiefs on vaccines, a representative stated that the “questions rely on flawed assumptions”.

“Her resume matches the responsibilities of her job,” the representative stated, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial one-day drug-approval program that reportedly concerned her predecessors. “How are these medications being chosen for this expedited pathway? Who takes the choices?” Howard said. “There is a lot of secrecy going on at the agency right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed rules of all drugs, with the exception of shots.”

Documented Past Work on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, history, critics said. She authored a research paper using unverified volunteer-provided data to estimate the rate of myocarditis following COVID-19 vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are riskier than they are.

Included in her “policy goals” for the current federal leadership encompassed revising guidelines for recently developed shots and halting “optional” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has according to sources suggested excluding young men from obtaining Covid vaccinations.

“She’s an complete ideologue who begins with her beliefs and works backwards to retrofit the data in a extremely misleading, dishonest manner,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|